Patents
Literature
3 results about "Tumor necrosis factor alpha" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Tumor necrosis factor (TNF, cachexin, or cachectin; once named as tumor necrosis factor alpha or TNFα) is a cell signaling protein (cytokine) involved in systemic inflammation and is one of the cytokines that make up the acute phase reaction. It is produced chiefly by activated macrophages, although it can be produced by many other cell types such as CD4+ lymphocytes, NK cells, neutrophils, mast cells, eosinophils, and neurons. TNF is a member of the TNF superfamily, consisting of various transmembrane proteins with a homologous TNF domain.
3-benzylamino coumarin compounds and uses thereof
The application belongs to the technical field of medicine, and relates to 3-benzylamino coumarin compounds and application thereof. Experimental results show that the compounds can significantly increase the survival rate of HUVEC cells in a high-sugar environment, and resist blood vessel injury caused by high sugar. The compounds can increase the release amount of NO in HUVEC cells damaged by high sugar, reduce the generation of malondialdehyde, and reduce the generation of tumor necrosis factor alpha.
Owner:JINAN SHANGCHENG MEDICAL TECH CO LTD +1
Treatment of psoriasis using small molecule inhibitors of tumor necrosis factor alpha
PendingJP2026518419AOrganic chemistryDermatological disorderTumor necrosis factor alphaPharmaceutical medicine
Owner:SANOFI SA(FR)
Biomarker combination for brain function detection and application
The invention provides a biomarker combination for detecting brain functional diseases. The biomarker combination comprises four protein markers, namely a glial fibrillary acidic protein (GFAP), an interleukin-6 (IL-6), an interleukin-1beta (IL-1beta) and a tumor necrosis factor alpha (TNF-alpha). The combined detection sensitivity of GFAP, IL-6, IL-1beta and TNF-alpha in a training column set can reach 85.26%, the specificity can reach 88.04%, and the area (AUC) under an ROC curve can reach 0.866. When the blood protein marker combination is used for preparing a reagent for detecting and evaluating the brain function of a patient, the disease diagnosis sensitivity can be improved, and the blood protein marker combination has the advantages of high specificity, good stability, rapid detection and the like. The biomarker combination disclosed by the invention can be applied to products for disease risk prediction, screening, prognosis evaluation, treatment effect monitoring or relapse monitoring and the like of brain function related diseases.
Owner:SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)